Dr. Daniel J. Krauss
Claim this profileWilliam Beaumont Hospital - Troy
Studies Prostate Cancer
Studies Prostate Adenocarcinoma
6 reported clinical trials
30 drugs studied
Affiliated Hospitals
Clinical Trials Daniel J. Krauss is currently running
Relugolix + Radiation
for Advanced-Stage Prostate Cancer
This phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with castration-sensitive prostate cancer that has spread to limited other parts of the body (oligometastatic). Relugolix is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the amount of testosterone (a male hormone) produced by the body. It may stop the growth of cancer cells that need testosterone to grow. Radiation therapy uses high-energy x rays or protons to kill tumor cells. The addition of relugolix to the radiation may reduce the chance of oligometastatic prostate cancer spreading further.
Recruiting0 awards Phase 2
Hormone Therapy + Radiation
for Prostate Cancer
This phase III trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread (metastasize) to other parts of the body. Decipher score in this study is used for patient selection and the two variations of treatment to be studied: intensification for higher Decipher score or de-intensification for low Decipher score. Patients with higher Decipher risk score will be assigned to the part of the study that compares the use of 6 months of the usual treatment (hormone therapy and radiation treatment) to the use of darolutamide plus the usual treatment (intensification). The purpose of this section of the study is to determine whether the additional drug can reduce the chance of cancer coming back and spreading in patients with higher Decipher score. The addition of darolutamide to the usual treatment may better control the cancer and prevent it from spreading. Alternatively, patients with low Decipher risk score will be assigned to the part of the study that compares the use of radiation treatment alone (de-intensification) to the usual approach (6 months of hormone therapy plus radiation). The purpose of this part of the study is to determine if radiation treatment alone is as effective compared to the usual treatment without affecting the chance of tumor coming back in patients with low Decipher score prostate cancer. Radiation therapy uses high energy to kill tumor cells and reduce the tumor size. Hormone therapy drugs such as darolutamide suppress or block the production or action of male hormones that play role in prostate cancer development. Effect of radiation treatment alone in patients with low Decipher score prostate cancer could be the same as the usual approach in stabilizing prostate cancer and preventing it from spreading, while avoiding the side effects associated with hormonal therapy.
Recruiting2 awards Phase 31 criteria
More about Daniel J. Krauss
Clinical Trial Related4 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Daniel J. Krauss has experience with
- Bicalutamide
- Radiation Therapy
- Buserelin
- Degarelix
- Flutamide
- Goserelin
Breakdown of trials Daniel J. Krauss has run
Prostate Cancer
Prostate Adenocarcinoma
Bladder Cancer
Renal Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daniel J. Krauss specialize in?
Daniel J. Krauss focuses on Prostate Cancer and Prostate Adenocarcinoma. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is Daniel J. Krauss currently recruiting for clinical trials?
Yes, Daniel J. Krauss is currently recruiting for 3 clinical trials in Sterling Heights Michigan. If you're interested in participating, you should apply.
Are there any treatments that Daniel J. Krauss has studied deeply?
Yes, Daniel J. Krauss has studied treatments such as Bicalutamide, Radiation Therapy, Buserelin.
What is the best way to schedule an appointment with Daniel J. Krauss?
Apply for one of the trials that Daniel J. Krauss is conducting.
What is the office address of Daniel J. Krauss?
The office of Daniel J. Krauss is located at: William Beaumont Hospital - Troy, Sterling Heights, Michigan 48314 United States. This is the address for their practice at the William Beaumont Hospital - Troy.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.